Clinical Trial Detail

NCT ID NCT03445533
Title A Study of IMO-2125 in Combination With Ipilimumab Versus Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma (ILLUMINATE 301)
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Idera Pharmaceuticals, Inc.
Indications

melanoma

Therapies

Ipilimumab

IMO-2125 + Ipilimumab

Age Groups: adult senior

No variant requirements are available.